Literature DB >> 24176918

A bismuth diethyldithiocarbamate compound promotes apoptosis in HepG2 carcinoma, cell cycle arrest and inhibits cell invasion through modulation of the NF-κB activation pathway.

Dayang Hazwani Abang Ishak1, Kah Kooi Ooi, Kok-Pian Ang, Abdah Md Akim, Yoke-Kqueen Cheah, Norshariza Nordin, Siti Nadiah Binti Abdul Halim, Hoi-Ling Seng, Edward R T Tiekink.   

Abstract

The compound with R=CH2CH3 in Bi(S2CNR2)3 (1) is highly cytotoxic against a range of human carcinoma, whereas that with R=CH2CH2OH (2) is considerably less so. Both 1 and 2 induce apoptosis in HepG2 cells with some evidence for necrosis induced by 2. Based on DNA fragmentation, caspase activities and human apoptosis PCR-array analysis, both the extrinsic and intrinsic pathways of apoptosis have been shown to occur. While both compounds activate mitochondrial and FAS apoptotic pathways, compound 1 was also found to induce another death receptor-dependent pathway by induction of CD40, CD40L and TNF-R1 (p55). Further, 1 highly expressed DAPK1, a tumour suppressor, with concomitant down-regulation of XIAP and NF-κB. Cell cycle arrest at the S and G2/M phases correlates with the inhibition of the growth of HepG2 cells. The cell invasion rate of 2 is 10-fold higher than that of 1, a finding correlated with the down-regulation of survivin and XIAP expression by 1. Compounds 1 and 2 interact with DNA through different binding motifs with 1 interacting with AT- or TA-specific sites followed by inhibition of restriction enzyme digestion; 2 did not interfere with any of the studied restriction enzymes.
© 2013.

Entities:  

Keywords:  Apoptosis; Bismuth; Cell cycle; Metallopharmaceuticals; NF-κB

Mesh:

Substances:

Year:  2013        PMID: 24176918     DOI: 10.1016/j.jinorgbio.2013.09.018

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  7 in total

1.  A new supramolecular based liquid solid microextraction method for preconcentration and determination of trace bismuth in human blood serum and hair samples by electrothermal atomic absorption spectrometry.

Authors:  Hadi Kahe; Mahmoud Chamsaz
Journal:  Environ Monit Assess       Date:  2016-10-03       Impact factor: 2.513

2.  A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells.

Authors:  Pit Foong Chan; Kok Pian Ang; Roslida Abd Hamid
Journal:  Biometals       Date:  2021-02-08       Impact factor: 2.949

3.  Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IκB/NF-κB, in atherosclerotic cell model.

Authors:  Ling Qiu; Rong Xu; Siyang Wang; Shuijun Li; Hongguang Sheng; Jiaxi Wu; Yi Qu
Journal:  Exp Mol Med       Date:  2015-07-03       Impact factor: 8.718

4.  Matrix metalloproteinase-1 induction by diethyldithiocarbamate is regulated via Akt and ERK/miR222/ETS-1 pathways in hepatic stellate cells.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Dong Zhang; Lin Liu; Hongyi Li; Qingling Zhai; Zhuo Li; Jidong Jia; Hong You
Journal:  Biosci Rep       Date:  2016-08-24       Impact factor: 3.840

5.  Bis[N-(2-hy-droxy-eth-yl)-N-iso-propyl-dithio-carbamato-κ(2) S,S'](piperazine-κN)cadmium: crystal structure and Hirshfeld surface analysis.

Authors:  Siti Artikah M Safbri; Siti Nadiah Abdul Halim; Mukesh M Jotani; Edward R T Tiekink
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-01-13

6.  Crystal structures of (2,2'-bipyridyl-κ(2) N,N')bis-[N,N-bis-(2-hydroxy-eth-yl)di-thio-carbamato-κ(2) S,S']zinc dihydrate and (2,2'-bipyridyl-κ(2) N,N')bis-[N-(2-hydroxy-eth-yl)-N-iso-propyl-dithio-carbamato-κ(2) S,S']zinc.

Authors:  Siti Artikah M Safbri; Siti Nadiah Abdul Halim; Edward R T Tiekink
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-01-20

Review 7.  Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?

Authors:  Chien Ing Yeo; Kah Kooi Ooi; Edward R T Tiekink
Journal:  Molecules       Date:  2018-06-11       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.